ANRO
Alto Neuroscience, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +7.1% ·
share flow -3.2% ·
net new positions +6.7%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 56 | +2 | 11.54M | $304.54M | +10 | −8 |
| Q1 2026 | 55 | +7 | 8.39M | $188.63M | +8 | −1 |
| Q4 2025 | 48 | +2 | 8.42M | $149.83M | +3 | −1 |
| Q3 2025 | 15 | +1 | 4.77M | $19.16M | +1 | — |
| Q2 2025 | 12 | 0 | 4.77M | $10.50M | +1 | −1 |
| Q1 2025 | 9 | +1 | 3.54M | $7.65M | +2 | −1 |
| Q4 2024 | 8 | +2 | 5.27M | $22.30M | +2 | — |
| Q3 2024 | 5 | 0 | 2.33M | $26.66M | +2 | −2 |
| Q2 2024 | 5 | — | 1.98M | $21.15M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 1.33M | +0.2% | $5.36M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passive) | 1.11M | +1.9% | $4.44M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 3 | Marshall Wace ✦ | 825.23K | -12.0% | $3.32M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 4 | BlackRock ✦ (passive) | 367.88K | -34.5% | $1.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 5 | Millennium Management ✦ | 315.76K | +4.3% | $1.27M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 237.90K | +3.6% | $956,864 | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Two Sigma Investments ✦ | 116.58K | +160.6% | $468,648 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passive) | 103.19K | -1.5% | $414,804 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Goldman Sachs Group ✦ | 90.25K | — | $362,809 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 75.77K | +118.4% | $304,603 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Morgan Stanley ✦ | 61.04K | — | $245,365 | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 12 | T. Rowe Price ✦ | 59.43K | 0.0% | $239,000 | 0.0% | Held | 6 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 37.15K | New | $149,351 | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 30.41K | -60.2% | $122,256 | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 15 | Fidelity (FMR) ✦ | 7.68K | -7.5% | $30,858 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $149,351 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 108 holders, 26.83M shares, $592.78M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 23.17K sh · $597,290
Officer · 886 sh · $23,807
Officer · 110.83K sh · $2.95M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology